Acacia hat heute informiert, dass sie durch eine Kapitalmassnahme 25 Mio. Eur eingenommen haben. Als Verwendungszweck geben sie an:
"Acacia Pharma intends to use the net proceeds of the Placing to:
recruit an initial sales force of approximately 30, with an additional ten support staff; pay marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement (both virtually and, where possible, in person) with key opinion leaders, healthcare professionals, and medical conference and speaker programmes; implement post-approval research and development commitments including paediatric studies for BARHEMSYS® and BYFAVO™ and a renal study for BARHEMSYS®; satisfy interest and capital payments under existing loan agreements; and general corporate purposes relating to ongoing commercial activities as well as supplementing existing stock of both BARHEMSYS® and BYFAVO™. "
|